Boehringer Ingelheim, Yuhan sign £689m NASH license deal

This article was originally published here

The fusion protein, which is being developed for NASH, utilises the HyFc technology of Genexine. It has been developed in-house by South Korean pharma company. The fusion protein

The post Boehringer Ingelheim, Yuhan sign £689m NASH license deal appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply